'Isolated' low high-density lipoprotein cholesterol

Annals of Pharmacotherapy

Volumn 31, Issue 1, 1997, Pages 89-97

  Wilt, Vickie M ^a   Gums, John G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; LOOP DIURETIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ALCOHOL CONSUMPTION; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; ESTROGEN THERAPY; EXERCISE; GALLSTONE FORMATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN METABOLISM; LIVER TOXICITY; META ANALYSIS; MULTICENTER STUDY; NEPHROTIC SYNDROME; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYNDROME X;

EID: 0031028250     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100115     Document Type: Review

References (65)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329-445.
2. NIH Consensus Conference. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
4. Grundy SM. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 1995;75:45B-52B.
5. Miller M, Kwiterovich PO Jr. Isolated low HDL-choIesterol as an important risk factor for coronary heart disease. Eur Heart J 1990;11 (suppl H):9-14.
6. Tall AR. Plasma high density lipoproteins metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
7. Frohlich JJ, Pritchard PH. The clinical significance of serum high density lipoproteins. Clin Biochem 1989;22:417-23.
8. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117-41.
9. Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am Heart J 1989;117:911-51.
10. Rosenson RS. Low levels of high-density lipoprotein cholesterol (hypoalphalipoproteinemia) an approach to management. Arch Intern Med 1993;153:1528-38.
11. Rubins HB, Schectman G, Wilt TJ, Iwane MK. Distribution of lipid phenotypes in community-living men with coronary heart disease. Arch Intern Med 1992;152:2412-6.
12. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) Am J Cardiol 1995;75:1189-95.
13. Silverman DI, Pasternak RC. High-density Iipoprotein subfractions. Am J Med 1993;94:636-45.
14. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
15. Gordon DJ, Rifkind BM. High-density Iipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
16. Drexel H, Amann FW, Beran J, Rentsch K, Candinas R, Muntwyler J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994;90:2230-5.
17. Gotto AM. Dyslipidemia and atherosclerosis a forecast of pharmaceutical approaches. Circulation 1993;87(suppl III):54-9.
18. Genest JJ Jr, Martin Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial Iipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33.
19. Karhapää P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes 1994;43:411-7.
20. Leighton RF. Management of the patient with low HDL-cholesterol. Clin Cardiol 1990;13:521-32.
21. Criqui MH, Cowan LD, Tyroler HA, Bangdiwalas S, Heiss G, Wallace RB, et al. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results from the Lipid Research Clinics Follow-up Study. Am J Epidemiol 1987:126:629-37.
22. Garrison RJ, Kannell WB, Feinleib M, Castelli WP, McNamara PM, Padgett SJ. Cigarette smoking and HDL-C; the Framingham Offspring Study. Atherosclerosis 1978;30:17-25.
23. Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis 1988;74:85-9.
24. Glantz SA, Parmley WW. Passive smoking and heart disease: epidemiology, physiology, and biochemistry. Circulation 1991;83:1-12.
25. Moskowitz WB, Mosteller M, Schicken RM, Bossano R, Hewitt JK, Bodurtha JN, et al. Lipoprotein and oxygen transport alterations in passive smoking preadolescent children: the MCV twin study. Circulation 1990;81:586-92.
26. Dannenberg AL, Keller JB, Wilson PWF, Castelli WP. Leisure time physical activity in the Framingham Offspring Study: description, seasonal variation, and risk factor correlates. Am J Epidemiol 1989:129:76-88.
27. Thompson PD, Cullinane EM, Sady SP, Flynn MM, Chenevert CB, Herbert PN, et al. High density Iipoprotein metabolism in endurance athletes and sedentary men. Circulation 1991;84:140-52.
28. Wood PD, Haskell WL, Blair SN, Willigas PT, Krauss RM, Lindgren FT, et al. Increased exercise level and plasma Iipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism 1983:32:31-9.
29. Tran ZV, Weltman A, Glass GV, Mood DP. The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies. Med Sci Sports Exerc 1983;15:393-402.
30. Kannell WB, Gordon T, Castelli WP. Obesity, lipids and glucose intolerance: the Framingham study. Am J Clin Nutr 1979;32:1238-45.
31. Brownell KD, Stunkard AJ. Differential changes in plasma high-density Iipoprotein cholesterol levels in obese men and women during weight reduction. Arch Intern Med 1981;141:1142-6.
32. Anderson KM, Wilson PWF, Garrison RJ, Castelli WP. Longitudinal and secular trends in Iipoprotein cholesterol measurement in a general population sample: the Framingham Offspring Study. Arterioscler Thromb VascBiol 1983;3:273-81.
33. Berns MA, DeVries JH, Katan MB. Increase in body fatness as a major determinant of changes in serum total cholesterol and high density lipoprotein cholesterol in young men over a 10-year period. Am J Epidemiol 1989;130:1109-22.
34. Langer RD, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation 1992;85:910-5.
35. Weidner G, Connor SL, Chesney MA, Burns JW, Connor WE, Matarazzo JD, et al. Sex differences in high density lipoprotein cholesterol among low-level alcohol consumers. Circulation 1991;83:176-80.
36. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992;267:961-8.
37. Godsland IF, Crook D, Simpson R, Proudler T, Feiton C, Lees B, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.
38. Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience. Am J Cardiol 1990;65:1287-91.
39. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease; a quantitative assessment of the epidemiologic evidence. PrevMedl991;20:47-63.
40. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
41. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
42. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
43. Cauley JA, LaPorte RE, Kuller LH, Bates M, Sandler RB. Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function. Atherosclerosis 1983:49:31-9.
44. Fahraeus L, Wallentin L. High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women. J Clin Endocrinol Metab 1983;56:797-801.
45. Jensen J, Nilas L, Christiansen C. Cyclic changes in serum cholesterol and lipoproteins following different doses of combined postmenopausal hormone replacement therapy. Br J Obstet Gynaecol 1986;93:613-8.
46. Krauss RM, Perlman JA, Ray R, Petitti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol 1988;158:1606-11.
47. Granfone A, Campos H, McNamara JR, Schefer MM, Lamon-Fava S, Ordovas JM, et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 1992;41:1193-8.
48. Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D, Matthys C, Warnick GR, et al. Lipoprotein, apolipoprotein, and Hpolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895-906.
49. Barter PJ. Management of low HDL cholesterol. Aust Fam Physician 1995:24:2066-74.
50. Pool JL, Taylor AA, Nelson EB. Review of the effects of doxazosin, a new selective alpha-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am J Med 1989;87(suppl 2A):57-61.
51. LaRosa JC, Cleeman JI. Cholesterol lowering as a treatment for established coronary heart disease. Circulation 1992;85:1229-35.
52. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980's. Am Heart J 1983;106:1191-200.
53. Kreisberg RA. Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it? Am J Med 1993;94:1-6.
54. Kolovou GD, Fostinis YP, Bilionou HI, Cokkinos DV. Response of high-density lipoproteins to hypolipidemic drugs according to their initial level. Am J Cardiol 1995;75:293-5.
55. Schulman KA, Kinosian B, Jacoboson TA, Click H, William MK, Kofler H, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-33.
56. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
57. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs. immediate release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
58. King JM, Grouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med 1994;97:323-31.
59. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-5.
60. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med 1996;156:1081-8.
61. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO Jr. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol; a randomized, double-blind, placebo-controlled, crossover study. Am J Med 1993;94:7-12.
62. Frick MH, Elo O, Haapa K, Heinonen O, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
63. Weintraub MS, Grosskopf I, Charach G, Mor R, Rubinstein A, Wollman Y, et al. Bezafibrate therapy in patients with isolated low high-density lipoprotein cholesterol levels may have a beneficial effect in prevention of atherosclerosis. Metabolism 1995;44:1401-9.
64. Vega GL, Grundy SM. Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia. JAMA 1989;262:3148-53.
65. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.